Observational Study of Rituxan in Rheumatoid Arthritis Patients in Routine Clinical Practice

A Phase IV, Post-marketing, Observational Study of Rituxan in Rheumatoid Arthritis Patients in Routine Clinical Practice

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00984711

Enrollment

150

Registered

2009-09-25

Start date

2007-05-31

Completion date

2015-12-31

Last updated

2010-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

This study was designed to gather data regarding the efficacy and safety of Rituxan in clinical practice whereby patients may present with concomitant medical conditions, medications as well as varying presentations of rheumatoid arthritis not always captured within the purer population seen in an industry sponsored clinical trial.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subjects with active rheumatoid arthritis as defined by ACR criteria * \> 18 years of age at time of consent * Able to start RITUXAN therapy per the approved product monograph within approximately 30 days of confirmed enrollment

Exclusion criteria

* Known Type 1 hypersensitivity or anaphylactic reactions to murine proteins, Chinese Hamster Ovary cell proteins or to any component of RITXAN as per approved Product monograph * Presence of any significant and or uncontrolled medical condition, which in the Investigator's opinion, precludes the use of RITUXAN as outlined in the Product Monograph

Countries

Canada

Contacts

Primary ContactLeeanna Bulinckx, RN, BScN

250-382-6270

Backup ContactChantal Vaillancourt, RN, BScN